Cambridge researchers making brain implants to treat Parkinson’s
Researchers at Cambridge are developing implants that could help repair damaged brain cells and treat diseases like Parkinson’s.
Drugs
Health
Research
Drugs
Pharma
Research
New insights on GLP-1 drugs: Benefits and risks unveiled
HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.
Drugs
Medical
Pharma
Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.
Health
Medical
Sleeping pills show promise in reducing Alzheimer’s proteins
HQ Team December 28, 2024: Research has shown a potential connection between the progression of Alzheimer’s disease in people who take sleeping pills..
Health
Medical
Taxi and ambulance drivers may have lower Alzheimer’s risk, study finds
HQ Team December 18, 2024: Taxi and ambulance drivers may have a lower risk of dying from Alzheimer’s disease compared to many other.
Drugs
Pharma
Breakthrough in halting dementia progression found by biotech company
HQ Team December 12, 2024: Filamon Limited, an Australian biotech company, has announced a significant advancement in dementia treatment with its new drug,.
Health
Medical
Belly fat during middle age linked to Alzheimer’s disease risk
Bharti Jayshankar December 3, 2024: If you are overweight and have accumulated body fat around your belly in your middle years then you.
Health
Medical
Brain shrinkage from Alzheimer’s therapy is desirable, not harmful: Study
Bharti Jayshankar December 2, 2024: A recent study by University College London (UCL) has revealed that the decrease in brain volume observed in.
Drugs
Health
Pharma
Cassava’s disputed Alzheimer’s drug flops in end-stage trials
Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.
Health
Uncategorized
EU regulators reverse course, approve Alzheimer’s drug Leqembi
HQ Team November 19, 2024: The European Medicines Agency (EMA) granted conditional approval for lecanemab, for the treatment of early Alzheimer’s disease in.